Verve Therapeutics (VERV) News Today $4.36 -0.02 (-0.46%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$4.36 0.00 (0.00%) As of 05/23/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VERV Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Verve Therapeutics, Inc. (NASDAQ:VERV) Position Lessened by Rafferty Asset Management LLCRafferty Asset Management LLC lowered its holdings in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 35.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 136,417 shares of the coMay 25 at 4:04 AM | marketbeat.comNorthern Trust Corp Raises Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)Northern Trust Corp increased its stake in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 12.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 650,562 shares of the company's stoMay 25 at 3:07 AM | marketbeat.comWall Street Zen Upgrades Verve Therapeutics (NASDAQ:VERV) to "Hold"Wall Street Zen upgraded Verve Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday.May 24 at 11:33 AM | marketbeat.comStrokes and Heart Attacks Kill. New Drugs Are Coming to Prevent Them.May 23 at 2:22 PM | msn.comHC Wainwright Has Optimistic Outlook of VERV FY2025 EarningsVerve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - Equities researchers at HC Wainwright raised their FY2025 earnings per share estimates for Verve Therapeutics in a report released on Monday, May 19th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per sharMay 23 at 8:29 AM | marketbeat.comMillennium Management LLC Sells 1,105,050 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)Millennium Management LLC decreased its position in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 22.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,919,131 shares of the company's stock after selling 1,105May 23 at 4:00 AM | marketbeat.comFY2025 EPS Estimate for Verve Therapeutics Lifted by AnalystMay 23 at 2:27 AM | americanbankingnews.comWhat is HC Wainwright's Estimate for VERV FY2026 Earnings?Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - HC Wainwright issued their FY2026 earnings per share (EPS) estimates for Verve Therapeutics in a note issued to investors on Monday, May 19th. HC Wainwright analyst M. Kapoor forecasts that the company will post earnings per share of ($2.65)May 22 at 7:40 AM | marketbeat.comResearch Analysts Offer Predictions for VERV FY2026 EarningsMay 22 at 2:40 AM | americanbankingnews.comVerve Therapeutics, Inc. (NASDAQ:VERV) Position Raised by Vestal Point Capital LPVestal Point Capital LP grew its position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 22.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 645,000 shares of the company's stock after purchasing an additional 120,000 sMay 21, 2025 | marketbeat.comPoint72 Asset Management L.P. Buys New Position in Verve Therapeutics, Inc. (NASDAQ:VERV)Point72 Asset Management L.P. bought a new stake in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 1,394,116 shares of the company's stock, valued at appMay 21, 2025 | marketbeat.comVerve Therapeutics Leads The Charge With 2 Other Promising Penny StocksMay 20, 2025 | finance.yahoo.comTema Etfs LLC Invests $503,000 in Verve Therapeutics, Inc. (NASDAQ:VERV)Tema Etfs LLC bought a new position in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 89,239 shares of the company's stock, valued at approximately $50May 20, 2025 | marketbeat.comCantor Fitzgerald Analysts Raise Earnings Estimates for VERVMay 20, 2025 | americanbankingnews.comCantor Fitzgerald Issues Positive Outlook for VERV EarningsVerve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - Equities research analysts at Cantor Fitzgerald lifted their FY2025 earnings estimates for shares of Verve Therapeutics in a research report issued to clients and investors on Thursday, May 15th. Cantor Fitzgerald analyst R. Bienkowski now anMay 20, 2025 | marketbeat.comQ3 EPS Forecast for Verve Therapeutics Lifted by AnalystVerve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - Analysts at William Blair raised their Q3 2025 earnings estimates for Verve Therapeutics in a research report issued on Wednesday, May 14th. William Blair analyst M. Minter now expects that the company will post earnings per share of ($0.73)May 20, 2025 | marketbeat.comQ3 EPS Forecast for Verve Therapeutics Raised by AnalystMay 20, 2025 | americanbankingnews.comAnalyst Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging HigherMay 19, 2025 | finance.yahoo.comVerve Therapeutics, Inc. (NASDAQ:VERV) Given Average Recommendation of "Buy" by BrokeragesMay 19, 2025 | americanbankingnews.comCubist Systematic Strategies LLC Has $663,000 Position in Verve Therapeutics, Inc. (NASDAQ:VERV)Cubist Systematic Strategies LLC lowered its stake in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 82.7% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 117,600 shares of the company's stock after selling 561,025 shares during the perMay 18, 2025 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Given Consensus Rating of "Buy" by AnalystsVerve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) has received an average rating of "Buy" from the six research firms that are currently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month price objMay 16, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Acquires 288,678 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)Jacobs Levy Equity Management Inc. increased its holdings in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 18.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,848,071 shares oMay 15, 2025 | marketbeat.comVerve Therapeutics Shares Rise After Narrower-Than-Expected 1Q LossMay 14, 2025 | marketwatch.comVerve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial ResultsMay 14, 2025 | globenewswire.comVerve Therapeutics (VERV) Expected to Announce Quarterly Earnings on WednesdayVerve Therapeutics (NASDAQ:VERV) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 14. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-14-verve-therapeutics-inc-stock/)May 9, 2025 | marketbeat.comVerve Therapeutics Stock Short Interest Report | NASDAQ:VERV | BenzingaMay 8, 2025 | benzinga.comVerve Therapeutics’ SWOT analysis: gene-editing stock shows promise amid challengesMay 7, 2025 | investing.comVerve Therapeutics, Inc. (NASDAQ:VERV) Stock Position Lifted by BVF Inc. ILBVF Inc. IL boosted its stake in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 962.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,904,050 shares of the company's stock after buMay 6, 2025 | marketbeat.comPDT Partners LLC Sells 128,512 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)PDT Partners LLC lessened its position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 70.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 53,291 shares of the company's stock after selMay 5, 2025 | marketbeat.comSusquehanna Fundamental Investments LLC Invests $1.64 Million in Verve Therapeutics, Inc. (NASDAQ:VERV)Susquehanna Fundamental Investments LLC acquired a new stake in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 291,383 shares of the company's stock,May 3, 2025 | marketbeat.comVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 | globenewswire.comSchonfeld Strategic Advisors LLC Boosts Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)Schonfeld Strategic Advisors LLC increased its holdings in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 57.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,789,379 shares of the comMay 2, 2025 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Shares Sold by T. Rowe Price Investment Management Inc.T. Rowe Price Investment Management Inc. trimmed its holdings in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 3.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,352,599 shares of the compaApril 30, 2025 | marketbeat.com1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall StreetApril 29, 2025 | fool.comSyon Capital LLC Takes $302,000 Position in Verve Therapeutics, Inc. (NASDAQ:VERV)Syon Capital LLC purchased a new position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 53,469 shares of the company's stApril 28, 2025 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Shares Sold by Renaissance Technologies LLCRenaissance Technologies LLC lessened its position in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 36.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 363,400 shares of the company's stApril 28, 2025 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Position Reduced by JPMorgan Chase & Co.JPMorgan Chase & Co. lowered its stake in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 74.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 417,539 shares of the company's stock after selling 1,230,305 shares during the period. JPMorgan Chase & Co. oApril 26, 2025 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Given Average Recommendation of "Buy" by AnalystsVerve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) has been assigned an average rating of "Buy" from the six ratings firms that are currently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12 month target price amoApril 21, 2025 | marketbeat.comWhy Verve Therapeutics Zoomed 40% Higher This WeekApril 18, 2025 | fool.comVerve Therapeutics Sees Unusually Large Options Volume (NASDAQ:VERV)Verve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) was the target of some unusual options trading on Tuesday. Traders acquired 7,528 call options on the company. This is an increase of approximately 2,795% compared to the average daily volume of 260 call options.April 17, 2025 | marketbeat.comGuggenheim Raises Verve Therapeutics (NASDAQ:VERV) Price Target to $24.00Guggenheim boosted their target price on shares of Verve Therapeutics from $18.00 to $24.00 and gave the company a "buy" rating in a report on Tuesday.April 17, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Upgraded to Overweight at Cantor FitzgeraldCantor Fitzgerald upgraded Verve Therapeutics from a "neutral" rating to an "overweight" rating in a report on Tuesday.April 17, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Stock Price Expected to Rise, Canaccord Genuity Group Analyst SaysCanaccord Genuity Group upped their price target on Verve Therapeutics from $32.00 to $39.00 and gave the stock a "buy" rating in a report on Tuesday.April 17, 2025 | marketbeat.comBiotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More NewsApril 17, 2025 | finance.yahoo.comHC Wainwright Forecasts Strong Price Appreciation for Verve Therapeutics (NASDAQ:VERV) StockHC Wainwright upped their price target on Verve Therapeutics from $15.00 to $25.00 and gave the stock a "buy" rating in a report on Monday.April 16, 2025 | marketbeat.comJ.P. Morgan Sticks to Their Hold Rating for Verve Therapeutics (VERV)April 16, 2025 | markets.businessinsider.comVerve extends gains as Cantor Fitzgerald upgrades on data for cholesterol drugApril 15, 2025 | msn.comVerve Therapeutics price target raised to $24 from $18 at GuggenheimApril 15, 2025 | markets.businessinsider.comCantor upgrades Verve Therapeutics to Overweight after positive dataApril 15, 2025 | markets.businessinsider.comWhy Verve Therapeutics Is Skyrocketing TodayApril 15, 2025 | fool.com Get Verve Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter. Email Address VERV Media Mentions By Week VERV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VERV News Sentiment▼0.850.77▲Average Medical News Sentiment VERV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VERV Articles This Week▼316▲VERV Articles Average Week Get Verve Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Edgewise Therapeutics News Today Immunocore News Today Travere Therapeutics News Today Mesoblast News Today Structure Therapeutics News Today Janux Therapeutics News Today Evotec News Today ARS Pharmaceuticals News Today Adaptive Biotechnologies News Today Vera Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VERV) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verve Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VERV Stock Free VERV Stock Alerts